ScripOtsuka’s release of supplemental Phase III data on June 6 for sibeprenlimab was the second major data readout in immunoglobulin A nephropathy (IgAN) of the week, following Vera’s Phase III data on Jun
Pink SheetThe Maryland Prescription Drug Affordability Board (PDAB) does not automatically assume an upper payment limit is the go-to solution for drug affordability concerns, Executive Director Andrew York sai
Generics BulletinFor the third time, the Federal Trade Commission has sent out warning letters to drug companies, disputing improperly listed patents in the US Food and Drug Administration’s Orange Book. In this round
ScripGilead Sciences division Kite is aiming for its bicistronic anti-CD19/CD20 CAR-T therapy KITE-363 to be able to both tamp down toxicity in patients with B-cell lymphomas and to prevent CD19-negative r